Peptech to present at key international conferencesMonday, 30...

Peptech to present at key international conferences
Monday, 30 April 2007 Sydney, Australia: Biotechnology company, Peptech Limited (ASX: PTD, AIM: PTDx) will be presenting to potential and existing investors and attendees at the following key international conferences over the coming month:
��
eG Capital Bio-Investment Forum 2007 – 1 May, San Francisco and 3 May, New York
��
Bio-relationships – 4 May, Boston
��
BIO International Convention 2007 - , 6 - 9 May, Boston
��
Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference – 14 - 15 May, Monaco
��
BioEquity Europe 2007 – 21 - 22 May, Glasgow
The presentation at these conferences will be made available on the company’s website tomorrow.
In addition to the Company announcement in March regarding the engagement of Citigroup to review strategic alternatives, Peptech is focused on maximising shareholder value and importantly ensuring the technology value associated with its pipeline is recognised in any transaction.
To date there have been three areas of review:
a) Transactions which take advantage of the significant appetite of private equity groups who clearly recognise the $1.77 of cash and cash equivalents inherent in Peptech’s stock price;
b) Review by international biotech companies attracted to the company’s strong product pipeline and cash position to support multiple products into the clinic; and
c)Transactions that allow Peptech to broaden its platform, products and partnerships in order to substantially grow its technology value before any further transactions are contemplated.
The sequencing of these options will be critical in maximising shareholder value. Management and the board are taking the appropriate time to determine the optimum strategy. The Peptech board is committed to developing a strategy with a focus on shareholder value.
Dr John Chiplin said: “The Peptech board is evaluating a breadth of strategic options. This, by necessity, does take considerable time, but the board recognises that it is important to consider all key options.”
“Notwithstanding, the consideration of strategic options, we are working hard at developing the company’s existing assets, with our lead compound PN0621 expected to enter clinical trials in the coming weeks, he added.”